EMA cuts MHRA out of drug reviews ahead of Brexit

The European Medicines Agency (EMA) has reportedly put a stop to the UK’s role in evaluating new EU medicines for sale as Brexit looms.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UK life sciences bodies submit concerns over ‘no deal’ Brexit

12 November 2018 Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

Big Pharma

MHRA seeks public views on no-deal Brexit

4 October 2018 The UK’s Medicines and Healthcare Products Regulatory Agency is seeking industry views on a no-deal Brexit scenario.

Big Pharma

No-deal Brexit: MHRA would take on EMA functions for UK

24 August 2018 The UK will fall outside of the European Medicines Agency in the event of a no-deal Brexit, leaving the Medicines and Healthcare Products Regulatory Agency to take on the functions currently undertaken by the EU for medicines on the UK market.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

EMA cuts MHRA out of drug reviews ahead of Brexit

More on this story

Editor's picks

Editor's picks

More features